Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
PaperCitations, authors & open-access status
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 626 citations, 2005 year and bronze oa status.
626
Citations
2005
Year
bronze
OA Status